Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Accunovo Biotechnologies
AddedMar 20, 2024
UpdatedJun 18, 2026
Accunovo Biotechnologies

Accunovo Biotechnologies

Innovating prostate cancer detection & treatment.

HQ
Chapel Hill, NC, US
Overview
Compare
Fundraising
Employees

Accunovo Biotechnologies focuses on innovating prostate cancer detection and treatment. The company aims to develop advanced detection and treatment agents to improve prostate cancer management, targeting the healthcare market with cutting-edge biotechnological solutions.

Accunovo Biotechnologies has made significant strides in the field of oncology, contributing to better clinical outcomes for prostate cancer patients. Their work has garnered attention for its potential to revolutionize cancer care, positioning the company as a key player in biotechnological advancements.

Accunovo Biotechnologies - Similar Companies

Onko Solutions logo

Onko Solutions

AccuraGen logo

AccuraGen

Evincis Bio logo

Evincis Bio

Acomhal Research logo

Acomhal Research

Accelerated Pharma logo

Accelerated Pharma

OncoHealth logo

OncoHealth

oncohealthcorp.com

Precision Theranostics logo

Precision Theranostics

Oncotect logo

Oncotect

oncotect.co

Nascent Biotech logo

Nascent Biotech

nascentbiotech.com

NovoThelium logo

NovoThelium

novothelium.com

AVnovum Therapeutics logo

AVnovum Therapeutics

AgNovos Healthcare logo

AgNovos Healthcare

Thunder Biotech logo

Thunder Biotech

thunderbiotech.com

Advanced Cancer Therapeutics logo

Advanced Cancer Therapeutics

Accelerated Medical Diagnostics logo

Accelerated Medical Diagnostics

Accunovo Biotechnologies - Quick Facts

Who are Accunovo Biotechnologies' competitors?

Companies similar to Accunovo Biotechnologies include Onko Solutions, AccuraGen, Evincis Bio and Acomhal Research.

Where is Accunovo Biotechnologies' headquarters located?

Accunovo Biotechnologies' headquarters is located in Chapel Hill, NC, US.

When was Accunovo Biotechnologies' last funding round?

Accunovo Biotechnologies' most recent funding round was for $75k (USD) in September 2022.

How much has Accunovo Biotechnologies raised to-date?

As of Sep 22, 2022, Accunovo Biotechnologies has raised a total of $75k (USD).

How many employees does Accunovo Biotechnologies have?

Accunovo Biotechnologies has 50 employees as of Feb 4, 2024.

Accunovo Biotechnologies - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Cancer Treatment
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified